Table 3. Results of the ReSVinet scale in the professional cohort (Group 1).
This table categorizes patients according to clinical, epidemiological and outcome variables in the cohort evaluated by three pediatricians.
| Observer 1 | Observer 2 | Observer 3 | Least significant association | |||
|---|---|---|---|---|---|---|
| Descriptive análisis1 | Mean (SD)2 | Mean (SD)2 | Mean (SD)2 | P-value3 | ||
| ReSVinet Score | 11.4 (3.4) | 10.6 (3.5) | 10.4 (3.1) | |||
| Sex | 0.101 (O3) | |||||
| Male | 63.5% (108/170) | 12.0 (3.4) | 11 (3.6) | 10.7 (3.1) | ||
| Female | 36.5% (62/170) | 10.5 (3.1) | 9.8 (3.2) | 9.8 (3.1) | ||
| Age | 0.790 (O2) | |||||
| < 1 year | 85.3% (145/170) | 10.9 (4.0) | 10.3 (3.8) | 10 (3.5) | ||
| 1–2 years | 14.7% (25/170) | 11.5 (3.3) | 10.6 (3.5) | 10.5 (3.1) | ||
| Previous wheezing episode | 0.012 (O3) | |||||
| Yes | 37.1% (62/167) | 12.9 (3.5) | 11.9 (3.9) | 11.3 (3.6) | ||
| No | 62.9% (105/167) | 10.6 (3) | 9.7 (3.1) | 9.9 (2.7) | ||
| Prematurity | 0.928 (O3) | |||||
| Yes | 8.4% (14/167) | 12.6 (4.3) | 10.7 (4.8) | 10.7 (3.7) | ||
| No | 91.6% (153/167) | 11.3 (3.3) | 10.5 (3.4) | 10.4 (3.1) | ||
| Nebulized epinephrine | 0.120 (O3) | |||||
| Yes | 57.6% (98/170) | 12 (3.5) | 11.1 (3.6) | 10.7 (3.7) | ||
| No | 42.4% (72/170) | 10.7 (3.2) | 9.8 (3.2) | 10.4 (3.1) | ||
| Antibiotics | < 0.001 | |||||
| Yes | 58.8% (100/170) | 12.4 (3.5) | 11.5 (3.4) | 11.3 (2.9) | ||
| No | 41.2% (70/170) | 10.1 (2.6) | 9.1 (3.2) | 9.1 (3) | ||
| Heliox | < 0.001 | |||||
| Yes | 37.3% (63/169) | 14.1 (3.2) | 13.3 (3.3) | 12.4 (2.9) | ||
| No | 62.7% (106/169) | 9.9 (2.4) | 8.9 (2.5) | 9.2 (2.6) | ||
| Suspected bacterian (super)infection | 0.001 (O2-O3) | |||||
| Yes | 41% (68/166) | 12.6 (3) | 11.6 (3.2) | 11.5 (2.7) | ||
| No | 59% (98/166) | 10.7 (3.4) | 9.9 (3.6) | 9.7 (3.2) | ||
| RSV detected4 | 0.739 (O2) | |||||
| Yes | 77.1% (128/166) | 11.4 (3.4) | 10.6 (3.5) | 10.7 (3) | ||
| No | 22.9% (38/166) | 11.7 (3.3) | 10.6 (3.6) | 9.8 (3.6) | ||
| PICU admission | < 0.001 | |||||
| Yes | 21.8% (37/170) | 15.7 (2.6) | 15.4 (2.7) | 14 (2.6) | ||
| No | 78.2% (133/170) | 10.2 (2.5) | 9.2 (2.4) | 9.4 (2.4) | ||
| Wood-Downes Score | <0.001 | |||||
| < = 3 | 27.6% (42/152) | 9.6 (2.9) | 8.2 (2.5) | 8.6 (2.8) | ||
| 4–6 | 50% (76/152) | 11.1 (2.7) | 10.2 (2.7) | 10.2 (2.5) | ||
| ≥7 | 22.4% (34/152) | 15.1 (3.1) | 14.7 (3.0) | 13.7 (2.9) | ||
| Hospital Length of Stay5 | 7.9 (3.9) | 0.49 | 0.48 | 0.60 | <0.001 | |
1 Descriptive analysis: Data are expressed either as % (n/total of patients for which this condition was recorded in medical history) or as mean (SD).
2 Mean (standard deviation) of ReSVinet scale according to each rater and the different variables. Correlation was assessed by Wilcoxon’s test for dichotomic variables, Kruskal-Wallis for discrete variables with more than two categories and Spearman’s correlation for continuous variables.
3 The p-value on the table represents the least significant one among all the observers (the case presenting the least significant value is indicated between brackets).
4 The method used for detecting RSV (Respiratory Syncytial Virus) in respiratory secretions of our patients was direct immunofluorescence.
5 Spearman’s correlation coefficient was used for the statistical analysis. Mean length of stay expressed as days (SD).